Enovis Corporation (NYSE:ENOV) Q4 2023 Results Conference Call February 22, 2024 8:30 AM ET

Company Participants

Kyle Rose - VP, IR

Matt Trerotola - CEO

Ben Berry - CFO

Conference Call Participants

Brandon Vazquez - William Blair

Caitlin Cronin - Canaccord Genuity

Dane Reinhardt - Baird

Danielle Antalffy - UBS

George Sellers - Stephens

Jason Wittes - Loop Capital

Vijay Kumar - Evercore ISI

Vik Chopra - Wells Fargo

Xuyang Li - Jefferies

Operator

Good morning, and welcome to the Enovis Fourth Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Kyle Rose, VP, Investor Relations. Please go ahead.

Kyle Rose

Good morning, everyone. Thank you for joining us today for our fourth quarter 2023 results conference call. I'm Kyle Rose, Vice President of Investor Relations. Joining me on the call this morning are Matt Trerotola, Chair and Chief Executive Officer; and Ben Berry, Chief Financial Officer.

Our earnings release was issued earlier this morning and is available in the Investors section of our website in enovis.com. We will be using a slide presentation in today's call, which can also be found on our website. Both the audio and the slide presentation of this call will be archived on the website later today.

During the call, we'll be making some forward-looking statements about our beliefs and estimates regarding future events and results. These forward-looking statements are subject to risks and uncertainties, including those set forth in the safe harbor language in today's earnings release and in our filings with the SEC. Actual results might differ materially from any forward-looking statements that we make. The forward-looking statements speak only as of today, and we do not assume any obligation or intend to update them, except as required by law.

With respect to any non-GAAP financial measures referenced during the call today, the accompanying reconciliation information relating to those measures can be found in our earnings press release and in the appendix of today's slide presentation.

With that, let me turn it over to Matt, who will begin on Slide 3. Matt?

Matt Trerotola

Thanks, Kyle. Hello, everyone, and thanks for joining us today. 2023 was a year of significant progress toward our long-term strategic goals, and I'm excited about the future of our high-value med tech growth company. We had a terrific year with continued share gains across geographies and business units, strong execution on new product initiatives, solid margin expansion, and truly transformative acquisitions.